Polyclonal B-cell and T-cell populations

Polyclonal B-cell and T-cell populations constitute the primary cellular components of the adaptive immune system, characterized by a diverse array of antigen receptors (T-cell receptors and B-cell receptors) derived from multiple cell clones (Janeway et al., 2001). T-cells are responsible for cell-mediated immunity, including the destruction of virally infected cells and the coordination of the immune response, while B-cells differentiate into plasma cells to produce specific antibodies (StatPearls, 2023). In therapeutic contexts, these populations are targeted to manage conditions where the immune system is overactive or misdirected, such as in organ transplantation to prevent rejection or in the treatment of severe autoimmune diseases (Mohty, 2006). Pharmacological agents like anti-thymocyte globulin (ATG) or alemtuzumab target these cells to induce rapid depletion via complement-dependent cytotoxicity and apoptosis (PubMed, PMID: 16434488). However, the broad depletion of these populations leads to significant safety concerns, including profound immunosuppression, increased risk of opportunistic infections, and potential development of secondary malignancies like post-transplant lymphoproliferative disorder (NIH, 2022). Because this entry refers to a heterogeneous cellular population rather than a specific molecular entity or receptor, it is classified as an incorrect or overly broad target for standard molecular pharmacology databases.

Other names

B and T lymphocytesPolyclonal lymphocytesAdaptive immune cellsLymphocyte populations

Depletion of lymphocytes through complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and induction of apoptosis; inhibition of lymphocyte activation, signal transduction, and clonal proliferation.